Justification of the composition and technology of combined tablets for the treatment of type II diabetes.

Authors

DOI:

https://doi.org/10.15587/2519-4852.2022.271046

Keywords:

type II diabetes therapy, derivatives of alpha-glucosidase inhibitors, voglibose, quercetin, solid dispersion, technology

Abstract

The aim. The aim of the work was to establish the feasibility of development, determine the optimal composition and technology, and confirm the pharmacological effectiveness of combined tablets for treating type II diabetes.

Materials and methods. Analytical research of the pharmaceutical market of drugs used for the treatment of type II diabetes was carried out using content analysis of official sources of information. The subjects of the study were medicinal products used to treat type II diabetes. A set of physicochemical and technological research methods was used to determine the quality parameters of the tabletting mass and tablets based on them.

Results. According to the results of previous studies, similarities in the approaches to the pharmacotherapy of type II diabetes in the countries of Southeast Asia, the Western Pacific region, and Ukraine were established, which became the basis for conducting a market study of drugs with a sugar-lowering effect, namely, based on voglibose, with the aim of further including such drugs in the range of Ukrainian manufacturers. Furthermore, according to the results of physicochemical and technological studies, the composition and rational technology of obtaining tablets were established. Also, pharmacological studies have established that tablets with voglibose and solid dispersion of quercetin significantly prevent the development of glucose metabolism disorders caused by a high-sugar diet. In terms of the expressiveness of the hypocholesterolemic effect of the tablets and their constituent components, they are reliably superior to the comparison drug - metformin.

Conclusions. According to the research results, the feasibility and relevance of the development of combined tablets with voglibose and solid dispersion of quercetin have been established. Furthermore, based on the investigated physicochemical and technological indicators, combined tablets' composition and rational technology were developed, and their specific pharmacological activity was proven

Author Biographies

Alla Kotvitska, National University of Pharmacy

Doctor of pharmaceutical sciences, Professor, Rector

 

Scopus Profile: link

Profile Google Scholar: link

ID ORCID: http://orcid.org/0000-0002-6650-1583

Professional (scientific) interests: development and implementation of social-effective standards and methods of pharmaceutical supply of the population in the context of compulsory health insurance and medicines' cost reimbursement implementation; social-effective mechanisms of providing the accessibility of pharmaceutical care for the population; legal and regulatory framework of medicines' turnover and pharmaceutical activity; development of pharmacoeconomical aspects of socially significant diseases treatment; analysis of medical and social measures of health indicators of the population.

 

Selected Publications:

1. Alla, A. K., Alina, V. C., Alina, V. V., Inna, V. K. (2018). Analysis of the current state and the dynamics of lipid-lowering drugs in the pharmaceutical market of Ukraine. Asian Journal of Pharmaceutical and Clinical Research, 11 (6), 358. doi: http://doi.org/10.22159/ajpcr.2018.v11i6.22702

2. Kotvitska, A. A., Kostiuk, V. H. (2018). The estimation of competitive positions of non-steroid anti-inflammatory drugs on pharmaceutical market of Ukraine. European Pharmaceutical Journal, 65 (1), 10–14. doi: http://doi.org/10.1515/afpuc-2017-0017

3. Rukhmakova, O. A., Yarnykh, T. G., Tykhonov, O. I., Kotvitska, A. A. (2018). Methodology for development of pediatric medicines for complex treatment of diseases of immune-dependent nature. Journal of Global Pharma Technology, 10 (12), 54–57.

4. Pashkov, V., Kotvitska, A., Harkusha, A. (2017). Legal regulation of the production and trade of medical devices and medical equipment in the EU and US: experience for Ukraine. Wiadomosci lekarskie, 70, 614-618. URL: https://www.ncbi.nlm.nih.gov/pubmed/28713093

5. Pashkov, V., Kotvitska, A., Noha, P. (2017). Protecting the rights of producers original medicines // Wiadomosci lekarskie. Vol. 70, Issue 4. P. 834–837.URL: https://www.ncbi.nlm.nih.gov/pubmed/29064813

6. Kotvitska, A. A., Zhyvora, N. V., Ovakimyan, O. S. (2018). Motivation of obtaining higher pharmaceutical education of students of the National Pharmaceutical University. Farmatsevtychnyi Zhurnal, 1-2, 41–50. doi: http://doi.org/10.32352/0367-3057.1-2.18.05

7. Kotvitska, A. A., Lobova, I. О. (2013). Marketing Researches of Market of Medications of Neuroprotective Action in Ukraine. Acta Facultatis Pharmaceuticae Universitatis Comenianae, 60 (1), 15–20. doi: http://doi.org/10.2478/afpuc-2013-0012

 

Olena Ruban, National University of Pharmacy

Doctor of Pharmaceutical Sciences, Professor, Head of Department

Department of Industrial Technology of Drugs

Alina Volkova, National University of Pharmacy

PhD, Associated Professor, Head of Department

Department of Social Pharmacy

Inna Kovalevska, National University of Pharmacy

Doctor of Pharmaceutical Sciences, Associate Professor

Department of Industrial Technology of Drugs

Nadiia Kononenko, National University of Pharmacy

Doctor of Medical Sciences, Professor, Head of Department

Department of Physiology and Pathological Physiology

Valentyna Chikitkina, National University of Pharmacy

PhD, Associate Professor

Department of Physiology and Pathological Physiology

References

  1. International Diabetes Federation (2019). IDF Diabetes Atlas. Brussels. Available at: https://diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf
  2. ICMR Guidelines for Management of Type 2 Diabetes (2018). Available at: https://main.icmr.nic.in/sites/default/files/guidelines/ICMR_GuidelinesType2diabetes2018_0.pdf
  3. Kovalevska, I., Ruban, O., Volkova, A., Kotvitska, A., Cherkashyna, A. (2022). The use of complex marketing analysis and QSPR methodology for the necessity of a drug development grounding for the treatment of type 2 diabetes mellitus with increased bioavailability. Pharmacia, 69 (2), 303–310. doi: https://doi.org/10.3897/pharmacia.69.e79179
  4. Kovalevska, I. V., Ruban, E. A., Kutsenko, S. A., Kutova, O. V., Kovalenko, Sv. M. (2017). Study of physical and chemical properties of solid dispersions of quercetin. Asian Journal of Pharmaceutics, 1 (4), 1–5.
  5. On approval and implementation of medical and technological documents for standardization of medical care for type 2 diabetes mellitus (2012). Order of the Ministry of Health of Ukraine No. 1118. 21.12.2012. Available at: https://zakon.rada.gov.ua/rada/show/v1118282-12#Text
  6. Guidelines for the prevention, management and care of diabetes mellitus (‎2006)‎. World Health Organization. Regional Office for the Eastern Mediterranean. Available at: https://apps.who.int/iris/handle/10665/119799
  7. Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G. et al. (2018). Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 61 (12), 2461–2498. doi: https://doi.org/10.1007/s00125-018-4729-5
  8. American Diabetes Association. Standards of Medical Care in Diabetes – 2018 (2018). Diabetes Care, 41 (1). doi: https://doi.org/10.2337/dc18-s015
  9. Weng, J., Ji, L., Jia, W., Lu, J., Zhou, Z., Zou, D. et al. (2016). Standards of care for type 2 diabetes in China. Diabetes/Metabolism Research and Reviews, 32 (5), 442–458. doi: https://doi.org/10.1002/dmrr.2827
  10. State Pharmacopoeia of Ukraine. Vol. 1 (2015). Kharkiv: State Enterprise "Scientific Expert Pharmacopoeia Center", 1135.
  11. Kovalevska, I. V., Hrudko, V. O. (2014). Doslidzhennia vplyvu tysku na rozchynnist kvertsetynu. Ukrainskyi visnyk psykhonevrolohii, 22 (79), 275–277.
  12. Ruban, O., Kononenko, N., Kovalevska, I., Chikitkina, V. (2021). Screening study of the antihyperglycemic action of new solid quercetin dispersions. ScienceRise: Pharmaceutical Science, 6 (34), 37–42. doi: https://doi.org/10.15587/2519-4852.2021.247443
  13. Kononenko, N. M., Ruban, O. A., Chikitkina, V. V., Kovalevska, I. V. (2020). The influence of antidiabetic combined medicinal product glikverin based on voglibose and quercetin on lipid exchange indices under conditions of experimental metabolic syndrome. Problems of Endocrine Pathology, 74 (4), 124–130. doi: https://doi.org/10.21856/j-pep.2020.4.16
  14. Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H. et al. (2020). Japanese Clinical Practice Guideline for Diabetes 2019. Journal of Diabetes Investigation, 11 (4), 1020–1076. doi: https://doi.org/10.1111/jdi.13306
  15. Portal of information Medguide.India. Available at: http://www.medguideindia.com/index.php
  16. Myers, E. F., Trostler, N., Varsha, V., Voet, H. (2017). Insights From the Diabetes in India Nutrition Guidelines Study. Topics in Clinical Nutrition, 32 (1), 69–86. doi: https://doi.org/10.1097/tin.0000000000000089
  17. State Register of Medicines of Ukraine. Information fund. Available at: http://www.drlz.com.ua/ibp/ddsite.nsf/all/index?opendocument
  18. Kovalevska, I., Ruban, O., Kutova, O., Levachkova, J. (2021). Optimization of the composition of solid dispersion of quercetin. Current Issues in Pharmacy and Medical Sciences, 34 (1), 1–4. doi: https://doi.org/10.2478/cipms-2021-0001
  19. Nemchenko, A. S., Toraev, K. N., Nazarkina, V. M. (2018). The analysis of the market of metformin-based drugs. Social Pharmacy in Health Care, 4 (1), 60–71. doi: https://doi.org/10.24959/sphhcj.18.107
  20. Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R. et al. (2017). Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Frontiers in Endocrinology, 8. doi: https://doi.org/10.3389/fendo.2017.00006
  21. Germanyuk, Т. А., Іvko, Т. І. (2014) Rational choice of monotherapy for the treatment of type 2 diabetes mellitus based on the pharmacoeconomical analysis. ScienceRise, 5 (4 (5)), 69–72.

Downloads

Published

2022-12-23

How to Cite

Kotvitska, A., Ruban, O., Volkova, A., Kovalevska, I., Kononenko, N., & Chikitkina, V. (2022). Justification of the composition and technology of combined tablets for the treatment of type II diabetes. ScienceRise: Pharmaceutical Science, (6(40), 58–65. https://doi.org/10.15587/2519-4852.2022.271046

Issue

No. 6(40) (2022)

Section

Pharmaceutical Science

License

Copyright (c) 2022 Alla Kotvitska, Olena Ruban, Alina Volkova, Inna Kovalevska, Nadiia Kononenko, Valentyna Chikitkina

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.